Martin Edelman, MD, Greenbaum Cancer Center, Baltimore, MD, says that organizations like NCCN and ASCO have guidelines for the management of non-small cell lung cancer (NSCLC). "I think that by utilizing these various clinical as well as biological markers, we can develop therapies that are tailored to the individual patient and have substantial evidence to support their use," said Dr Edelman.

 

This video was taken on May 2, 2013, at the NAMCP Spring Managed Care Forum in Orlando, FL.